Abenex, a long-standing European private equity player, is delighted to announce the completion of its investment in Santis LAB
Abenex partners with Santis LAB (‘Santis’), a Franco-Swiss laboratory developing and marketing food supplements with health benefits. This investment in Santis is perfectly aligned with the Abenex Funds’ investment strategy. The team has indeed a proven track record and expertise in health & wellness sectors. The CEO and the two co-founders, who will also retain operational roles, will invest alongside Abenex.
Founded in 2013, Santis benefits from a very strong scientific framework enabling it to implement its diverse range of food supplements in a network of c.2,000 pharmacies. Santis has developed formulations based on natural active ingredients combining phytotherapy, aromatherapy, minerals, apitherapy, probiotics and vitamins.
The company has dedicated R&D, training and pharmacy network management functions. The Group has achieved a strong and consistent growth trajectory since its inception, largely due to its leading position in the health-promoting products market.
The arrival of Abenex will enable Santis to consolidate its market position, while also accelerating its development in adjacent markets and new geographies.
Marie-Laetitia Le Roux, CEO of Santis LAB, comments “We welcome Abenex’s investment to support our continued growth. It was essential for our team to be associated with a reliable and experienced partner.”
For Etienne de Laroullière and Gildas Le Roux, co-founders of Santis LAB, “Abenex was an obvious choice given their in-depth market knowledge and ability to anticipate and understanding of address Santis’ future development goals.”
Paul Bertrand, Partner, adds “We are thrilled to announce our partnership with Marie-Laetitia, which will provide invaluable support to the company as it embarks on this new phase. We firmly believe that Santis benefits from robust fundamentals and is strategically positioned to capture new market shares.”
